Johnson & Johnson Initiates Second Global P-III Study of its COVID-19 Vaccine

 Johnson & Johnson Initiates Second Global P-III Study of its COVID-19 Vaccine

Johnson & Johnson Initiates Second Global P-III Study of its COVID-19 Vaccine

Shots:

  • In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial in collaboration with the UK NIHR
  • The P-lll ENSEMBLE 2 study will evaluate the safety and efficacy of a two-dose regimen of the investigational Janssen vaccine for the prevention of COVID-19 in ~30,000 patients across the globe. The ENSEMBLE and ENSEMBLE 2 trials will run in parallel
  • The two P-III studies follow positive interim results of P-I/IIa study assessing the safety profile and immunogenicity of both a single-dose/ two-dose vaccination

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Philadelphia Inquirer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post